Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L13a pseudogene 18 (RPL13AP18) is a non-coding processed pseudogene in the human genome. It does not produce a functional protein and has no known physiological or therapeutic role. It is one of several pseudogenes arising from the RPL13A gene, which codes for ribosomal protein L13a, a component of the large 60S ribosomal subunit. Pseudogenes like RPL13AP18 are typically regarded as genetically silent, although exceptions exist in rare cases. All known biological, disease, and drug-interaction functions pertain to the gene RPL13A and its protein product, not the pseudogene RPL13AP18[4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L13a pseudogene 18 (RPL13AP18).